4.8 Article

BRCA2 antagonizes classical and alternative nonhomologous end-joining to prevent gross genomic instability

期刊

NATURE COMMUNICATIONS
卷 8, 期 -, 页码 -

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/s41467-017-01759-y

关键词

-

资金

  1. Key Program of the National Natural Science Foundation of China [31730021]
  2. National Natural Science Funds for Distinguished Young Scholar
  3. National Program for Special Support of Eminent Professionals
  4. National Natural Science Foundation of China [81661128008, 31571397]
  5. National Postdoctoral Program for Innovative Talents [BX201600134]

向作者/读者索取更多资源

BRCA2-deficient cells exhibit gross genomic instability, but the underlying mechanisms are not fully understood. Here we report that inactivation of BRCA2 but not RAD51 destabilizes RPA-coated single-stranded DNA (ssDNA) structures at resected DNA double-strand breaks (DSBs) and greatly enhances the frequency of nuclear fragmentation following cell exposure to DNA damage. Importantly, these BRCA2-associated deficits are fueled by the aberrant activation of classical (c)- and alternative (alt)-nonhomologous end-joining (NHEJ), and rely on the well-defined DNA damage signaling pathway involving the pro-c-NHEJ factor 53BP1 and its downstream effector RIF1. We further show that the 53BP1-RIF1 axis promotes toxic end-joining events via the retention of Artemis at DNA damage sites. Accordingly, loss of 53BP1, RIF1, or Artemis prolongs the stability of RPA-coated DSB intermediates in BRCA2-deficient cells and restores nuclear integrity. We propose that BRCA2 antagonizes 53BP1, RIF1, and Artemis-dependent c-NHEJ and alt-NHEJ to prevent gross genomic instability in a RAD51-independent manner.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Review Medicine, Research & Experimental

Venetoclax combined with hypomethylating agents or low-dose cytarabine as induction chemotherapy for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy: a systematic review and meta-analysis

Yao Qin, Pu Kuang, Ting Liu

Summary: Venetoclax combined with hypomethylating agents or low-dose cytarabine may be an effective and well-tolerated treatment option for untreated AML patients who cannot tolerate intensive chemotherapy. A meta-analysis of four clinical trials showed higher complete remission rates and median overall survival time in this treatment combination, with common adverse events including nausea, diarrhea, and hypokalemia.

CLINICAL AND EXPERIMENTAL MEDICINE (2023)

Article Oncology

Tislelizumab for Relapsed/Refractory Classical Hodgkin Lymphoma: 3-Year Follow-up and Correlative Biomarker Analysis

Yuqin Song, Quanli Gao, Huilai Zhang, Lei Fan, Jianfeng Zhou, Dehui Zou, Wei Li, Haiyan Yang, Ting Liu, Quanshun Wang, Fangfang Lv, Haiyi Guo, Xia Zhao, Dan Wang, Pei Zhang, Yidi Wang, Lei Wang, Tengfei Liu, Yun Zhang, Zhirong Shen, Jane Huang, Jun Zhu

Summary: This study presents the extended 3-year follow-up of tislelizumab in patients with relapsed/refractory cHL, showing long-term benefits and a favorable safety profile.

CLINICAL CANCER RESEARCH (2022)

Article Endocrinology & Metabolism

Estrogen-Responsive Gene MAST4 Regulates Myeloma Bone Disease

Yushan Cui, Fangfang Wang, Danfeng Zhang, Jingcao Huang, Yan Yang, Juan Xu, Yuhan Gao, Hong Ding, Ying Qu, Wenyan Zhang, Weiping Liu, Ling Pan, Li Zhang, Zhigang Liu, Ting Niu, Ting Liu, Yuhuan Zheng

Summary: This study found that estrogen cell signaling negatively regulated multiple myeloma bone disease (MMBD) through the regulation of the MAST4 gene.

JOURNAL OF BONE AND MINERAL RESEARCH (2022)

Article Cell Biology

ALCAM regulates multiple myeloma chemoresistant side population

Fangfang Wang, Zhang Dan, Hongmei Luo, Jingcao Huang, Yushan Cui, Hong Ding, Juan Xu, Zhimei Lin, Yuhan Gao, Xinyu Zhai, Yan Yang, Ying Qu, Li Zhang, Fengjiao Chen, Qiang Wang, Xin Wang, Yu Feng, Ting Liu, Qing Yi, Ting Niu, Yuhuan Zheng

Summary: Drug-resistance is a major problem in multiple myeloma (MM) patients. This study reveals that activated-leukocyte-cell-adhesion-molecule (ALCAM) regulates MM side population (SP)-mediated drug-resistance through the ALCAM-EGF/EGFR axis. EGFR activation promotes the SP ratio, while ALCAM inhibits EGFR downstream signaling in MM cells. SP MM cells have a higher number of mitochondria and interference of mitochondrial function inhibits SP-genesis. Combination therapy with an anti-MM agent and EGFR inhibitor gefitinib improves MM therapeutic efficacy and prolongs survival in MM-bearing mice.

CELL DEATH & DISEASE (2022)

Article Hematology

Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients: Multi-center, single-arm, open-label, phase 2 study

Wei Xu, Keshu Zhou, Tingyu Wang, Shenmiao Yang, Lihong Liu, Yu Hu, Wei Zhang, Kaiyang Ding, Jianfeng Zhou, Sujun Gao, Bing Xu, Zunmin Zhu, Ting Liu, Huilai Zhang, Jianda Hu, Chunyan Ji, Shunqing Wang, Zhongjun Xia, Xin Wang, Yan Li, Yongping Song, Shuo Ma, Xinran Tang, Bin Zhang, Jianyong Li

Summary: Orelabrutinib demonstrated significant efficacy and safety in patients with refractory or relapsed CLL/SLL, with an overall response rate of 92.5%. The median progression-free survival had not been reached at a 32.3-month median follow-up. Moreover, Orelabrutinib showed promising response in patients with high prognostic risks.

AMERICAN JOURNAL OF HEMATOLOGY (2023)

Article Hematology

Chronic active Epstein-Barr virus infection involving gastrointestinal tract with hemophagocytic lymphohistiocytosis

Kai Shen, Xiao Shuai, Jianjun Li, Jiazhuo Liu, Ting Liu, Ting Niu, Hongbing Ma

Summary: This case series study summarizes the clinical features, treatment, and prognosis of gastrointestinal chronic active EBV infection (CAEBV) with hemophagocytic lymphohistiocytosis (HLH). The study highlights the importance of early recognition and the possibility of salvage therapy combining surgery, novel therapeutic agents, and/or autologous hematopoietic stem cell transplantation (HSCT).

ANNALS OF HEMATOLOGY (2023)

Article Multidisciplinary Sciences

Alternative telomere maintenance mechanism in Alligator sinensis provides insights into aging evolution

Yu-Zu Guo, Yi Zhang, Qing Wang, Jun Yu, Qiu-Hong Wan, Jun Huang, Sheng-Guo Fang

Summary: Alligators are suitable for studying anti-aging molecular mechanisms because they have low adult mortality rates and no significant telomere shortening. Selection analyses have shown that certain genes in alligators have undergone positive selection, and ALT-related genes are expressed at higher levels, which may contribute to anti-aging strategies.

ISCIENCE (2023)

Article Medicine, General & Internal

Severe Microcytic Anemia Caused by Complex Hereditary Spherocytosis and X-Linked Sideroblastic Anemia with Mutations in SPTB and ALAS2 Genes

Jianying Zhou, Hang Zhang, Yao Qin, Ting Liu

Summary: We present a case of severe anemia in a 16-year-old male with complex hereditary spherocytosis (HS) and X-linked sideroblastic anemia (XLSA) caused by mutations in the spectrin beta (SPTB) and 5-aminolevulinic acid synthase (ALAS2) genes. Next-generation sequencing revealed double heterozygous mutations in exon 19 of the SPTB gene (c.3936G > A:p.W1312X) and exon 2 of the ALAS2 gene (c.37A > G:p.K13E). The mutations were confirmed by Sanger sequencing. The mutations in the SPTB and ALAS2 genes contribute to the more severe clinical phenotypes observed in this patient.

JOURNAL OF CLINICAL MEDICINE (2023)

Review Oncology

Post-transplant cyclophosphamide versus anti-thymocyte globulin in allogeneic hematopoietic stem cell transplantation from unrelated donors: A systematic review and meta-analysis

Lu Tang, Zhigang Liu, Tao Li, Tian Dong, Qiuhui Wu, Ting Niu, Ting Liu, Jie Ji

Summary: Through investigating 1091 articles, it was found that the PTCy prophylaxis regimen can reduce the incidence of aGVHD, decrease NRM and EBV-related complications, and achieve better OS compared to the ATG-based regimen. There was no significant difference between the two groups in cGVHD, RI, CMV reactivation, and BKV-related HC.

FRONTIERS IN ONCOLOGY (2023)

Article Oncology

A novel conditioning regimen of chidamide, cladribine, gemcitabine, and busulfan in the autologous stem cell transplantation of aggressive T-cell lymphoma

Qiang Zeng, Hang Zhang, Pu Kuang, Jian Li, Xinchuan Chen, Tian Dong, Qiuhui Wu, Chuanli Zhang, Chunping Chen, Ting Niu, Ting Liu, Zhigang Liu, Jie Ji

Summary: The conditioning regimen of chidamide, cladribine, gemcitabine, and busulfan (ChiCGB) was effective in improving the prognosis of patients with peripheral T-cell (PTCL) or lymphoblastic T-cell lymphoma (T-LBL) undergoing autologous stem cell transplantation (ASCT). The regimen resulted in favorable overall survival and progression-free survival, with manageable adverse events. Randomized controlled trials are needed to further evaluate ChiCGB as a conditioning regimen for ASCT.

FRONTIERS IN ONCOLOGY (2023)

Article Hematology

Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, open-label, multicenter, single-arm study

Li-Juan Deng, Ke-Shu Zhou, Li-Hong Liu, Ming-Zhi Zhang, Zhi-Ming Li, Chun-Yan Ji, Wei Xu, Ting Liu, Bing Xu, Xin Wang, Su-Jun Gao, Hui-Lai Zhang, Yu Hu, Yan Li, Ying Cheng, Hai-Yan Yang, Jun-Ning Cao, Zun-Min Zhu, Jian-Da Hu, Wei Zhang, Hong-Mei Jing, Kai-Yang Ding, Xiang-Yang Zhang, Ren -Bin Zhao, Bin Zhang, Ya -Min Tian, Yong-Ping Song, Yu-Qin Song, Jun Zhu

Summary: Orelabrutinib demonstrates significant efficacy and tolerability in patients with relapsed or refractory mantle cell lymphoma, with a high overall response rate and median progression-free survival.

BLOOD ADVANCES (2023)

Article Hematology

Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma: A phase 2, multicenter, open-label study

Lijuan Deng, Zhiming Li, Huilai Zhang, Haiwen Huang, Jianda Hu, Lihong Liu, Ting Liu, Jie Jin, Zunmin Zhu, Wenyu Li, Zhenqian Huang, Wenrong Huang, Keshu Zhou, Haiyan Yang, Mingzhi Zhang, Kaiyang Ding, Hui Zhou, Yu Hu, Yuerong Shuang, Junning Cao, Sujun Gao, Dengju Li, Zimin Sun, Qingyuan Zhang, Shuhua Yi, Chunyan Ji, Liansheng Zhang, Cheng Hou, Yue Du, Weige Wang, Renbin Zhao, Yuqin Song, Jun Zhu

Summary: Orelabrutinib, a new-generation oral drug, demonstrated high response rates and good tolerability in patients with marginal zone lymphoma (MZL).

AMERICAN JOURNAL OF HEMATOLOGY (2023)

Article Medicine, General & Internal

Evaluation of orelabrutinib monotherapy in patients with relapsed or refractory Waldenstrom's macroglobulinemia in a single-arm, multicenter, open-label, phase 2 study

Xin-Xin Cao, Jie Jin, Cheng-Cheng Fu, Shu-Hua Yi, Wei-Li Zhao, Zi-Min Sun, Wei Yang, Deng-Ju Li, Guo-Hui Cui, Jian-da Hu, Ting Liu, Yong-Ping Song, Bing Xu, Zun-Min Zhu, Wei Xu, Ming-Zhi Zhang, Ya-Min Tian, Bin Zhang, Ren-Bin Zhao, Dao-Bin Zhou

Summary: Orelabrutinib has shown good efficacy and manageable safety profiles in patients with relapsed or refractory Waldenstrom's macroglobulinemia (R/R WM). The primary endpoint of this prospective study was to evaluate the major response rate (MRR) of orelabrutinib, which was found to be 80.9%, with an overall response rate of 89.4%.

ECLINICALMEDICINE (2022)

Article Hematology

Efficacy and safety blinatumomab in chinese adults with Ph-negative relapsed/refractory B-cell Precursor acute lymphoblastic leukemia: A multicenter open-label single-arm China registrational study

Hongsheng Zhou, Qingsong Yin, Jie Jin, Ting Liu, Zhen Cai, Bin Jiang, Dengju Li, Zimin Sun, Yan Li, Yanjuan He, Liping Ma, Sujun Gao, Jianda Hu, Aili He, Xin Du, Daihong Liu, Xiaohong Zhang, Xiaoyan Ke, Junling Zhuang, Yue Han, Xiaoqin Wang, Yuqi Chen, Paul Gordon, Dong Yu, Gerhard Zugmaier, Jianxiang Wang

Summary: This Chinese registrational study evaluated the safety and efficacy of Blinatumomab in Chinese adults with Ph- R/R BCP-ALL. The results showed that Blinatumomab had comparable efficacy and safety in these heavily pre-treated patients as compared to those in global clinical trials.

HEMATOLOGY (2022)

暂无数据